Bone marrow recovery of hematopoietic stem cells and microenvironment after chemotherapy in childhood acute lymphoblastic leukemia: consecutive observations according to chemotherapy schedule. (19th May 2019)

• Record Type: Journal Article
• Authors: Park, Sang Hyuk; Lee, Mee Jeong; Park, Chan-Jeoung; Jang, Seongsoo; Seo, Eul-Ju; Im, Ho-Joon; Seo, Jong-Jin
• Is Part Of: Pediatric hematology and oncology. Volume 36:Number 4(2019)
• Page Start: 222
• Page End: 235
• Publication Date: 2019-05-19
• Subjects: Bone marrow recovery -- chemotherapy -- childhood acute lymphoblastic leukemia -- hematopoietic stem cell -- microenvironment; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Hematologic Diseases -- Child; Hematologic Diseases -- Infant; Neoplasms -- Child; 618.9215
• DOI: 10.1080/08880018.2019.1623354
• Languages: English
• ISSNs: 0888-0018

Abstract

Abstract: We investigated bone marrow (BM) recovery of hematopoietic stem cells (HSC) and hematopoietic microenvironment after chemotherapy in childhood acute lymphoblastic leukemia (ALL). Twenty-nine de novo childhood ALL patients were enrolled and BM biopsy sections at diagnosis (BM0), after induction (BM1), consolidation (BM3), interim maintenance (BM5) and delayed intensification (BM7) chemotherapy were obtained. Expressions of CD133, CD34, CD117, osteopontin, osteonectin, CXCL12, and CXCR4 were evaluated by semiquantitative immunohistochemical stains. All markers recovered significantly following chemotherapy while highest values at BM3 (for CD133/CD117/CXCL12/CXCR4), BM5 (for CXCL12/CD34/osteonectin), and BM7 (for osteopontin). Patients with cytogenetic good risk expressed significantly more CD133 + /CD34 + cells than those with standard and poor risk in BM5. Patients without aberrant immunophenotype expressed significantly more CD133 + cells in BM1, and more CD117 + cells in BM5 than those with aberrant immunophenotype. Patients treated with standard risk-average chemotherapeutic protocol expressed significantly more CXCR4 + cells than those treated with other protocols in BM7. Patients who showed lowest ANC ≥ 200/µL during induction chemotherapy expressed significantly more CXCR4 + cells at from BM1 to BM5, and more CD133 + cells in BM3 than those who did not. Early and full recovery of BM HSC is most vigorous at BM3 and BM5, respectively. Reconstruction of BM niche and stromal cell recovery is mostly active at BM5, and hematopoietic activity of BM niche recovers mostly at BM7. Patients with cytogenetic good risk, nonaberrant immunophenotype, standard risk-average chemotherapeutic protocol and less BM suppression during induction chemotherapy show prompt recovery of some BM HSC and microenvironment markers compared to others.